Introduction: Infectious complications represent a major cause of morbidity and mortality in hairy cell leukemia (HCL) patients. Due to the immunosuppressive nature of the disease, these patients are frequently affected by opportunistic infections and rare pathogens. Furthermore, cytotoxic chemotherapy might lead to poor or even fatal outcomes in the setting of an active infection. Case Presentation: We report the case of a 62-year-old HCL patient who presented with recurrent fever episodes, pancytopenia, and mediastinal lymphadenopathy. A treatment decision against purine analogs and for rituximab mono was made as lymph node tissue revealed disseminated Mycobacterium kansasii infection. Together with specific antimycobacterial treatment, rituximab mono led to complete hematologic remission after 6 months without aggravating the accompanying infection. Conclusion: Here, we demonstrate successful treatment of HCL with rituximab in a patient with concomitant disseminated M. kansasii infection.

Keywords:
Mycobacterium kansasii, Nontuberculous mycobacteria, Mycobacteria, Hairy cell leukemia, Rituximab
1.
Maitre
 
E
,
Cornet
 
E
,
Troussard
 
X
.
Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment
.
Am J Hematol
.
2019
;
94
(
12
):
1413
–
22
.
https://doi.org/10.1002/ajh.25653
.
Google Scholar
Crossref
Search ADS
PubMed
 
2.
Grever
 
MR
,
Abdel-Wahab
 
O
,
Andritsos
 
LA
,
Banerji
 
V
,
Barrientos
 
J
,
Blachly
 
JS
,  
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
.
Blood
.
2017
;
129
(
5
):
553
–
60
.
https://doi.org/10.1182/blood-2016-01-689422
.
Google Scholar
Crossref
Search ADS
PubMed
 
3.
Hoefsloot
 
W
,
van Ingen
 
J
,
Andrejak
 
C
,
Angeby
 
K
,
Bauriaud
 
R
,
Bemer
 
P
,  
The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study
.
Eur Respir J
.
2013
;
42
(
6
):
1604
–
13
.
https://doi.org/10.1183/09031936.00149212
.
Google Scholar
Crossref
Search ADS
PubMed
 
4.
Bennett
 
C
,
Vardiman
 
J
,
Golomb
 
H
.
Disseminated atypical mycobacterial infection in patients with hairy cell leukemia
.
Am J Med
.
1986
;
80
(
5
):
891
–
6
.
https://doi.org/10.1016/0002-9343(86)90634-0
.
Google Scholar
Crossref
Search ADS
PubMed
 
5.
Ramasamy
 
C
,
Dubashi
 
B
,
Sree Rekha
 
J
,
Basu
 
D
,
Jain
 
A
,
Dutta
 
TK
.
Atypical mycobacterial infection in hairy cell leukemia treated with cladribine
.
Indian J Hematol Blood Transfus
.
2014
;
30
(
1
):
59
–
61
.
https://doi.org/10.1007/s12288-012-0196-1
.
Google Scholar
Crossref
Search ADS
PubMed
 
6.
Thomas
 
DA
,
O’Brien
 
S
,
Bueso-Ramos
 
C
,
Faderl
 
S
,
Keating
 
MJ
,
Giles
 
FJ
,  
Rituximab in relapsed or refractory hairy cell leukemia
.
Blood
.
2003
;
102
(
12
):
3906
–
11
.
https://doi.org/10.1182/blood-2003-02-0630
.
Google Scholar
Crossref
Search ADS
PubMed
 
7.
Grever
 
M
,
Andritsos
 
L
,
Banerji
 
V
,
Barrientos
 
JC
,
Bhat
 
S
,
Blachly
 
JS
,  
Hairy cell leukemia and COVID-19 adaptation of treatment guidelines
.
Leukemia
.
2021
;
35
(
7
):
1864
–
72
.
https://doi.org/10.1038/s41375-021-01257-7
.
Google Scholar
Crossref
Search ADS
PubMed
 
8.
Maneikis
 
K
,
Šablauskas
 
K
,
Ringelevičiūtė
 
U
,
Vaitekėnaitė
 
V
,
Čekauskienė
 
R
,
Kryžauskaitė
 
L
,  
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study
.
Lancet Haematol
.
2021
;
8
(
8
):
e583
–
92
.
Google Scholar
Crossref
Search ADS
PubMed
 
© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.